This technology is a screening tool for identifying individuals with increased risk of developing major depressive disorder (MDD).
Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting over 300 million people. Development of an early detection test, and subsequent implementation of preventive interventions could help reduce the worldwide prevalence of MDD and associated economic burden.
This technology is a screening tool for detecting individuals who are most susceptible to developing MDD, and allows for targeted preventive interventions by identifying the children of parents who carry the endophenotype for depression. Using positron emission tomography (PET), this technology quantifies serotonin 1A receptor binding potential and compares results to a predetermined threshold to distinguish between individuals with and without MDD. Machine learning-based, multivoxel pattern analyses are then applied to accurately classify high- and low-risk individuals. This technology may reduce the prevalence of MDD by enabling early preventive intervention and can also be used to track the efficacy of treatment.
This technology has been validated in a pilot study of human subjects with MDD, high-risk of MDD, and healthy volunteers.
IR CU18160
Licensing Contact: Jerry Kokoshka